. Author manuscript; available in PMC: 2021 Oct 1.

Published in final edited form as: Nat Med. 2021 Mar 4;27(4):717–726. doi: 10.1038/s41591-021-01294-w

Table 1.

Monoclonal antibodies used in this study

	MAb	Region	Species	EC50 values (ng/mL)^a		block ACE2 binding	Contact residues within RBM^b	Binding site residues, aa position	Functionally important residues^c	Other mapping data	References
	MAb	Region	Species	D614G	E484K/D614G	block ACE2 binding	Contact residues within RBM^b	Binding site residues, aa position	Functionally important residues^c	Other mapping data	References
CLASS 1	COV2–2196	RBD - RBM	human	3	16	yes	yes	455–456, 475–479, 484–489, 493	F486A, N487A (LOB)	Not competitive with COV2–2130	^5,19,58
	COV2–2130	RBD - RBM	human	22	36	yes	yes	345–346, 439–441, 443–447, 449–450, 452, 484, 490, 492–494	K444A, G447R (LOB); and R346I, K444R, K444E (NE)	Not competitive with COV2–2196	^5,19,58
	COV2–2072	RBD - RBM	human	6	19	yes	yes	N/A	N/A	COV2–2196 competitive	^5,19
	COV2–2050	RBD - RBM	human	4	>10,000	yes	yes	N/A	E484K (LOB and NE)	COV2–2196 and COV2–2130 competitive	^5,19,31
	COV2–3025	RBD - RBM	human	3	14	yes	yes	N/A	N/A	COV2–2196 competitive	^5,19
	COV2–2381	RBD - RBM	human	5	28	yes	yes	N/A	N/A	COV2–2196 competitive	^5,19
	1B07	RBD - RBM	mouse-human chimera	2	>10,000	yes	yes	N/A	E484A/D/G/K, F486Y (NE)	N/A	^20,33
	S2E12	RBD - RBM	human	4	17	yes	yes	455 to 458, 473 to 493	G476S, F486A (LOB)	N/A	⁷, Starr, Corti et al. unpublished
	COVOX-384	RBD - RBM	human	3	>10,000	yes	yes	455–456, 456, 482–486	N/A	N/A	⁵⁷
	COVOX-40	RBD - RBM	human	60	95	yes	yes	417, 409, 505	N/A	N/A	⁵⁷
	S2H58	RBD-RBM	human	6	>10,000	yes	yes	N/A	E484K, F490L, S494P (LOB)		Starr, Corti et al. unpublished
	S2X259	RBD	human	99	105	yes	no		G504D (LOB)		⁵⁶
CLASS 2	S309	RBD- BASE	human	314	375	no	no	333–335,337, 339–341, 343, 346,354, 356–361, 440–441, 444,509	N/A	N/A	³
	SARS2–3	RBD- BASE	mouse	4187	9331	no	no	N/A	N/A	CR3022 competitive	VanBlargan and Diamond, unpublished
	SARS2–10	RBD- BASE	mouse	1258	833	yes	no	N/A	N/A	CR3022 competitive	VanBlargan and Diamond, unpublished
	SARS2–31	RBD- BASE	mouse	130	282	yes	no	N/A	K378E/Q, R408K, G504D (NE)	CR3022 competitive	VanBlargan and Diamond, unpublished
	SARS2–44	RBD- BASE	mouse	59	269	yes	no	N/A	N/A	CR3022 competitive	VanBlargan and Diamond, unpublished
CLASS 3	COV2–2676	NTD	human	2496	3575	no	no	N/A	Y144A, N164A (LOB) and F140S (NE)	COV2–2489 competitive	^5,19,21
CLASS 3	COV2–2489	NTD	human	6854	6795	no	no	N/A	G142A, Y144A, F157A, N164A (LOB); and G142D, R158S (NE)	COV2–2676 competitive	^5,19,21

Neutralization potency determined by FRNT assay in Vero-hACE2-TMPRSS2 cells from Figure 1 with D614G and E484K/D614G isolates.

Identified as engaging residues within the RBM site by direct binding ELISA or by epitope mapping using loss-of binding assays.

LOB, loss-of-binding to spike protein, and NE, neutralization escape mutants assessed with SARS-CoV-2 WA1/2020.

N/A, data not available